{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:59:48Z","timestamp":1780923588010,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.287","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:24:03Z","timestamp":1779233043000},"page":"243-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer screening: Decision-making when MRI results are inconclusive for cancer (PI-RADS 3)"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-2838","authenticated-orcid":false,"given":"Stuart G.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.04.287_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.287_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12894-025-01986-2","article-title":"To biopsy or not biopsy, that is the question: PI-RADS 3 prostate lesions: validation of clinical and radiological parameters for biopsy decision-making","volume":"25","author":"Franz","year":"2025","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.287_bib0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000003788","article-title":"Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial","volume":"211","author":"Mian","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.287_bib0004","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233337","article-title":"Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis","volume":"312","author":"Oerther","year":"2024","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.287_bib0005","first-page":"13","article-title":"Review of clinically significant cancer in lesions labeled PI-RADS 3 on MRI using PI- RADS version 2.1","volume":"52","author":"Satei","year":"2023","journal-title":"Appl Radiol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.287_bib0006","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221309","article-title":"Prospective evaluation of PI-RADS version 2.1 for prostate cancer detection and investigation of multiparametric MRI-derived markers","volume":"307","author":"Yilmaz","year":"2023","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.287_bib0007","article-title":"PI-RADS 3 MRI lesions: are biopsies still necessary?","volume":"35","author":"Long Depaquit","year":"2025","journal-title":"Fr J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.287_bib0008","article-title":"Predictors of prostate cancer detection in MRI PI-RADS 3 lesions: reality of a tertiary center","volume":"95","author":"Ara\u00fajo","year":"2023","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.urolonc.2026.04.287_bib0009","first-page":"99","article-title":"PI-RADS 3 lesions: a comprehensive analysis of malignancy prevalence, institutional comparison, and predictive factors","volume":"32","author":"Premanand","year":"2025","journal-title":"TPM"},{"issue":"18","key":"10.1016\/j.urolonc.2026.04.287_bib0010","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.34355","article-title":"Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions","volume":"128","author":"Fang","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.287_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.10.002","article-title":"Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: how wide is the gap?","volume":"43","author":"Smani","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.287_bib0012","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1002\/sim.8319","article-title":"Maximum likelihood estimation with missing outcomes: from simplicity to complexity","volume":"38","author":"Baker","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.04.287_bib0013","article-title":"Evaluation of clinical prediction models (part 2): how to undertake an external validation study","volume":"384","author":"Riley","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2026.04.287_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.urolonc.2026.04.287_bib0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"ProtecT study group. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2026.04.287_bib0016","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMsb1616281","article-title":"prostate cancer screening - a perspective on the current state of the evidence","volume":"376","author":"Pinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.287_bib0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00345-024-04776-x","article-title":"PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions","volume":"42","author":"Kwe","year":"2024","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.287_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/febs.70207","article-title":"Principal mechanisms of extracellular matrix-mediated cell-cell communication in physiological and tumor microenvironments","volume":"293","author":"Piperigkou","year":"2026","journal-title":"FEBS J"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.287_bib0019","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/cancers17091491","article-title":"The role of the extracellular matrix in cancer prevention","volume":"17","author":"Baker","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.287_bib0020","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.7150\/thno.39995","article-title":"Towards extracellular matrix normalization for improved treatment of solid tumors","volume":"10","author":"Abyaneh","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.urolonc.2026.04.287_bib0021","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/carcin\/bgab052","article-title":"The case for a cancer paradox initiative","volume":"42","author":"Baker","year":"2021","journal-title":"Carcinogenesis"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926004965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926004965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:04:28Z","timestamp":1780920268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926004965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1078143926004965"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.287","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer screening: Decision-making when MRI results are inconclusive for cancer (PI-RADS 3)","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}